The Motor Study

ALS is a disease of the nervous system that affects nerve cells in the brain and spinal cord, it causes loss of muscle control, and worsens over time. The study drug is administered as an oral tablet.

While there are a few approved treatments for ALS, they only slow progression of symptoms, extending survival. The goal of this study is to stop the condition from progressing and potentially even partially reversing it.

The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.

Nucleus Network will be conducting Part A and B of this study at our Melbourne facility. Nucleus Network is not conducting Part C - ALS patient.

Interested participants for the healthy volunteer trial (Part A and B) can express their interest in joining this critical clinical trial by calling 1800 243 733 or by registering interest via the below link.

For Part C – ALS patient arm will occur across other facilities in Adelaide, Sydney, and Brisbane. The selection of principal investigators for these studies is in progress. Please check the Clinical Trials website for more details on Part C - ALS patient.